Varlirix (GlaxoSmithKline). Current opinion in investigational drugs Arvin, A. M. 2002; 3 (7): 996-999

Abstract

GlaxoSmithKline (formerly SmithKline Beecham) has developed and launched Varilrix, a preparation of live, attenuated Oka-strain varicella zoster virus, for immunization against varicella zoster infections [455138]. By the end of 1998, Varilrix was available in a few European countries and in India [284490], [455138]. By 2001, the vaccine was also available in Brazil and Hong Kong [396267].

View details for PubMedID 12186278